{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:55:33Z","timestamp":1786982133656,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11912-024-01620-8","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T02:14:53Z","timestamp":1733451293000},"page":"1664-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable"],"prefix":"10.1007","volume":"26","author":[{"given":"Julio","family":"Cartagena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anagha","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazie","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rimsza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"1620_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/leu.2009.19","volume":"23","author":"M Wang","year":"2009","unstructured":"Wang M, Sun L, Qian J, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23:1320\u20138.","journal-title":"Leukemia"},{"key":"1620_CR2","doi-asserted-by":"publisher","first-page":"106605","DOI":"10.1016\/j.leukres.2021.106605","volume":"108","author":"X Wu","year":"2021","unstructured":"Wu X, Lu H, Pang T, et al. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: a meta-analysis. Leuk Res. 2021;108:106605.","journal-title":"Leuk Res"},{"key":"1620_CR3","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684\u201392.","journal-title":"Br J Cancer"},{"key":"1620_CR4","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","volume":"10","author":"TE Lew","year":"2023","unstructured":"Lew TE, Minson A, Dickinson M, et al. Treatment approaches for patients with TP53-mutated mantle cell lymphoma. Lancet Haematol. 2023;10:e142\u201354.","journal-title":"Lancet Haematol"},{"key":"1620_CR5","doi-asserted-by":"publisher","first-page":"348","DOI":"10.5732\/cjc.011.10469","volume":"31","author":"ZT Ying","year":"2012","unstructured":"Ying ZT, Zheng W, Wang XP, et al. The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma. Chin J Cancer. 2012;31:348\u201353.","journal-title":"Chin J Cancer"},{"key":"1620_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388:565\u201375.","journal-title":"Lancet"},{"key":"1620_CR7","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","volume":"377","author":"S Le Gouill","year":"2017","unstructured":"Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377:1250\u201360.","journal-title":"N Engl J Med"},{"key":"1620_CR8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/ajh.25226","volume":"93","author":"T Hilal","year":"2018","unstructured":"Hilal T, Wang Z, Almader-Douglas D, Rosenthal A, Reeder CB, Jain T. Rituximab maintenance therapy for mantle cell lymphoma: a systematic review and meta-analysis. Am J Hematol. 2018;93:1220\u20136.","journal-title":"Am J Hematol"},{"key":"1620_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203\u201310.","journal-title":"Lancet"},{"key":"1620_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2022-163018","volume":"140","author":"M Dreyling","year":"2022","unstructured":"Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140:1\u20133.","journal-title":"Blood"},{"key":"1620_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"1620_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41571-023-00821-7","volume":"21","author":"ERS Cliff","year":"2024","unstructured":"Cliff ERS, Hilal T, Kesselheim AS. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma. Nat Rev Clin Oncol. 2024;21:1\u20132.","journal-title":"Nat Rev Clin Oncol"},{"key":"1620_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1182\/blood-2020-134824","volume":"136","author":"M Wang","year":"2020","unstructured":"Wang M, Rule S, Zinzani P, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2020;136:38\u20139.","journal-title":"Blood"},{"key":"1620_CR14","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","volume":"5","author":"CS Tam","year":"2021","unstructured":"Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2021;5:2577\u201385.","journal-title":"Blood Adv"},{"key":"1620_CR15","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","volume":"127","author":"P Martin","year":"2016","unstructured":"Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127:1559\u201363.","journal-title":"Blood"},{"key":"1620_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"1620_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR t-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1620_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1358\/dot.2022.58.6.3378055","volume":"58","author":"A Deshpande","year":"2022","unstructured":"Deshpande A, Wang Y, Munoz J, Jain P. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Drugs Today (Barc). 2022;58:283\u201398.","journal-title":"Drugs Today (Barc)"},{"key":"1620_CR19","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, et al. Three-year follow-up of kte-x19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the zuma-2 study. J Clin Oncol. 2023;41:555\u201367.","journal-title":"J Clin Oncol"},{"key":"1620_CR20","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, Nastoupil L, Westin J, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192:e38\u201342.","journal-title":"Br J Haematol"},{"key":"1620_CR21","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol. 2023;41:3988\u201397.","journal-title":"J Clin Oncol"},{"key":"1620_CR22","doi-asserted-by":"crossref","unstructured":"Wu S, Blombery P, Westerman D, Tam CS. Utility of measurable residual disease (MRD) assessment in mantle cell lymphoma. Curr Treat Options Oncol 2023.","DOI":"10.1007\/s11864-023-01102-2"},{"key":"1620_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1182\/blood.V84.2.403.403","volume":"84","author":"M Hummel","year":"1994","unstructured":"Hummel M, Tamaru J, Kalvelage B, Stein H. Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood. 1994;84:403\u20137.","journal-title":"Blood"},{"key":"1620_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008;22:771\u201382.","journal-title":"Leukemia"},{"key":"1620_CR25","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJM van Dongen","year":"2015","unstructured":"van Dongen JJM, van der Velden VHJ, Br\u00fcggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996\u20134009.","journal-title":"Blood"},{"key":"1620_CR26","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1097\/HS9.0000000000000347","volume":"4","author":"D Drandi","year":"2020","unstructured":"Drandi D, Alcantara M, Benmaad I, et al. Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network. Hemasphere. 2020;4:e347.","journal-title":"Hemasphere"},{"key":"1620_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s12185-023-03566-2","volume":"117","author":"R Shirai","year":"2023","unstructured":"Shirai R, Osumi T, Keino D, et al. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia\/lymphoma. Int J Hematol. 2023;117:910\u20138.","journal-title":"Int J Hematol"},{"key":"1620_CR28","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1182\/blood.V83.7.1871.1871","volume":"83","author":"R Rimokh","year":"1994","unstructured":"Rimokh R, Berger F, Delsol G, et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood. 1994;83:1871\u20135.","journal-title":"Blood"},{"key":"1620_CR29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","volume":"107","author":"C Pott","year":"2006","unstructured":"Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood. 2006;107:2271\u20138.","journal-title":"Blood"},{"key":"1620_CR30","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115:3215\u201323.","journal-title":"Blood"},{"key":"1620_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3324\/haematol.11267","volume":"93","author":"S Bottcher","year":"2008","unstructured":"Bottcher S, Ritgen M, Buske S, et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica. 2008;93:551\u20139.","journal-title":"Haematologica"},{"key":"1620_CR32","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"M Cheminant","year":"2016","unstructured":"Cheminant M, Derrieux C, Touzart A, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101:336\u201345.","journal-title":"Haematologica"},{"key":"1620_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cyto.b.21893","volume":"98","author":"E Bayly","year":"2020","unstructured":"Bayly E, Nguyen V, Binek A, et al. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma. Cytometry B Clin Cytom. 2020;98:385\u201398.","journal-title":"Cytometry B Clin Cytom"},{"key":"1620_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1182\/blood-2019-129323","volume":"134","author":"M Smith","year":"2019","unstructured":"Smith M, Jegede O, Parekh S, et al. Minimal residual disease (MRD) Assessment in the ecog1411 randomized phase 2 trial of front-line bendamustine-rituximab (br)-based induction followed by rituximab (r) \u00b1 lenalidomide (l) consolidation for mantle cell lymphoma (MCL). Blood. 2019;134:751.","journal-title":"Blood"},{"key":"1620_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"C Morgane","year":"2016","unstructured":"Morgane C, Coralie D, Aurore T, et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica. 2016;101:336\u201345.","journal-title":"Haematologica"},{"key":"1620_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","volume":"20","author":"T Ching","year":"2020","unstructured":"Ching T, Duncan ME, Newman-Eerkes T, et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 2020;20:612.","journal-title":"BMC Cancer"},{"key":"1620_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2013.375","volume":"28","author":"M Ladetto","year":"2014","unstructured":"Ladetto M, Bruggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299\u2013307.","journal-title":"Leukemia"},{"key":"1620_CR38","first-page":"11","volume":"136","author":"ZD Epstein-Peterson","year":"2020","unstructured":"Epstein-Peterson ZD, Batlevi CL, Caron P, et al. Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: phase ii, investigator-initiated. Single-Center Study Blood. 2020;136:11\u20132.","journal-title":"Single-Center Study Blood"},{"key":"1620_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.clml.2023.12.006","volume":"24","author":"A Rezazadeh","year":"2024","unstructured":"Rezazadeh A, Pruett J, Detzner A, et al. Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2024;24:254\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1620_CR40","first-page":"6407","volume":"140","author":"F Furqan","year":"2022","unstructured":"Furqan F, Fenske T, Longo W, Johnson B, Hamadani M, Shah N. MRD Status by clonoseq \u00ae is a poor predictor of long-term outcomes after bispecific lv20.19 CAR t-cell therapy for relapsed. Refractory B-Cell NHL Blood. 2022;140:6407\u20138.","journal-title":"Refractory B-Cell NHL. Blood"},{"key":"1620_CR41","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1182\/blood-2023-188338","volume":"142","author":"S Ananth","year":"2023","unstructured":"Ananth S, Su Y-J, Hamilton MP, et al. Post-CAR-T minimal residual disease (MRD) monitoring in mantle cell lymphoma enables early relapse detection. Blood. 2023;142:1673.","journal-title":"Blood"},{"key":"1620_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17:223\u201338.","journal-title":"Nat Rev Cancer"},{"key":"1620_CR43","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985\u201390.","journal-title":"Nat Med"},{"key":"1620_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.","journal-title":"J Hematol Oncol"},{"key":"1620_CR45","doi-asserted-by":"publisher","first-page":"2052410","DOI":"10.1080\/2162402X.2022.2052410","volume":"11","author":"S Kato","year":"2022","unstructured":"Kato S, Li B, Adashek JJ, et al. Serial changes in liquid biopsy-derived variant allele frequency predict immune checkpoint inhibitor responsiveness in the pan-cancer setting. Oncoimmunology. 2022;11:2052410.","journal-title":"Oncoimmunology"},{"key":"1620_CR46","first-page":"3600","volume":"13","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis treatment and screening. Cancers. 2021;13:3600.","journal-title":"Treatment and Screening Cancers"},{"issue":"30","key":"1620_CR47","first-page":"e1","volume":"28","author":"AM Goodman","year":"2022","unstructured":"Goodman AM, Holden KA, Jeong AR, et al. Assessing CAR t-cell therapy response using genome-wide sequencing of cell-free dna in patients with b-cell lymphomas. Transplant Cell Ther. 2022;28(30):e1\u20137.","journal-title":"Transplant Cell Ther"},{"key":"1620_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25:119\u201329.","journal-title":"Nat Med"},{"key":"1620_CR49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378:1211\u201323.","journal-title":"N Engl J Med"},{"key":"1620_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1158\/1078-0432.CCR-21-2183","volume":"28","author":"CM Stewart","year":"2022","unstructured":"Stewart CM, Michaud L, Whiting K, et al. Phase I\/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring. Clin Cancer Res. 2022;28:45\u201356.","journal-title":"Clin Cancer Res"},{"key":"1620_CR51","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","volume":"6","author":"R Lakhotia","year":"2022","unstructured":"Lakhotia R, Melani C, Dunleavy K, et al. Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Adv. 2022;6:2667\u201380.","journal-title":"Blood Adv"},{"key":"1620_CR52","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/nm.3729","volume":"20","author":"Z Zheng","year":"2014","unstructured":"Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479\u201384.","journal-title":"Nat Med"},{"key":"1620_CR53","doi-asserted-by":"publisher","first-page":"e09083","DOI":"10.7554\/eLife.09083","volume":"4","author":"Y Yang","year":"2015","unstructured":"Yang Y, Wang C, Yang Q, et al. Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoires. eLife. 2015;4:e09083.","journal-title":"eLife"},{"key":"1620_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-020-00961-8","volume":"13","author":"D Jung","year":"2020","unstructured":"Jung D, Jain P, Yao Y, Wang M. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol. 2020;13:127.","journal-title":"J Hematol Oncol"},{"key":"1620_CR55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","volume":"13","author":"L Burgos","year":"2020","unstructured":"Burgos L, Puig N, Cedena MT, et al. Measurable residual disease in multiple myeloma: ready for clinical practice? J Hematol Oncol. 2020;13:82.","journal-title":"J Hematol Oncol"},{"key":"1620_CR56","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"1620_CR57","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"1620_CR58","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood.2022016170","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140:2423\u20138.","journal-title":"Blood"},{"key":"1620_CR59","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","volume":"8","author":"JD Soumerai","year":"2021","unstructured":"Soumerai JD, Mato AR, Dogan A, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Haematology. 2021;8:e879\u201390.","journal-title":"The Lancet Haematology"},{"key":"1620_CR60","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2019001077","volume":"134","author":"PA Thompson","year":"2019","unstructured":"Thompson PA, Srivastava J, Peterson C, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood. 2019;134:1951\u20139.","journal-title":"Blood"},{"key":"1620_CR61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clml.2019.03.014","volume":"19","author":"S Molica","year":"2019","unstructured":"Molica S, Giannarelli D, Montserrat E. Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19:423\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1620_CR62","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1200\/JCO.22.02283","volume":"41","author":"T Munir","year":"2023","unstructured":"Munir T, Moreno C, Owen C, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the glow study. J Clin Oncol. 2023;41:3689\u201399.","journal-title":"J Clin Oncol"},{"key":"1620_CR63","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica. 2022;107:2783\u201393.","journal-title":"Haematologica"},{"key":"1620_CR64","doi-asserted-by":"publisher","first-page":"101407","DOI":"10.1016\/j.beha.2022.101407","volume":"35","author":"AC Logan","year":"2022","unstructured":"Logan AC. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough? Best Pract Res Clin Haematol. 2022;35:101407.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1620_CR65","doi-asserted-by":"publisher","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","volume":"3","author":"DA Berry","year":"2017","unstructured":"Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.","journal-title":"JAMA Oncol"},{"key":"1620_CR66","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/ajh.24200","volume":"90","author":"A Freedman","year":"2015","unstructured":"Freedman A. Follicular lymphoma: 2015 update on diagnosis and management. Am J Hematol. 2015;90:1171\u20138.","journal-title":"Am J Hematol"},{"key":"1620_CR67","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1200\/JCO.21.01234","volume":"40","author":"S Luminari","year":"2022","unstructured":"Luminari S, Manni M, Galimberti S, et al. Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the foll12 study. J Clin Oncol. 2022;40:729\u201339.","journal-title":"J Clin Oncol"},{"key":"1620_CR68","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/bjh.14996","volume":"180","author":"ML Chase","year":"2018","unstructured":"Chase ML, Armand P. Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions. Br J Haematol. 2018;180:177\u201388.","journal-title":"Br J Haematol"},{"key":"1620_CR69","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.23.00838","volume":"42","author":"C Pott","year":"2024","unstructured":"Pott C, Jurinovic V, Trotman J, et al. Minimal residual disease status predicts outcome in patients with previously untreated follicular lymphoma: a prospective analysis of the phase III GALLIUM study. J Clin Oncol. 2024;42:550\u201361.","journal-title":"J Clin Oncol"},{"key":"1620_CR70","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1182\/bloodadvances.2022007706","volume":"7","author":"RW Merryman","year":"2023","unstructured":"Merryman RW, Redd RA, Taranto E, et al. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023;7:4748\u201359.","journal-title":"Blood Adv"},{"key":"1620_CR71","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1200\/JCO.2023.41.16_suppl.7547","volume":"41","author":"B Miles","year":"2023","unstructured":"Miles B, Mao D, Vardhanabhuti S, et al. Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL). Journal of Clinical Oncology. 2023;41:7547.","journal-title":"Journal of Clinical Oncology"},{"key":"1620_CR72","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ctrv.2024.102691","volume":"124","author":"J Munoz","year":"2024","unstructured":"Munoz J, Deshpande A, Rimsza L, Nowakowski GS, Kurzrock R. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL. Cancer Treat Rev. 2024;124:102691.","journal-title":"Cancer Treat Rev"},{"key":"1620_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s43018-021-00204-w","volume":"2","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Goloubev A, Kato S, Kurzrock R. Missing the target in cancer therapy. Nat Cancer. 2021;2:369\u201371.","journal-title":"Nat Cancer"},{"key":"1620_CR74","first-page":"6407","volume":"140","author":"F Furqan","year":"2022","unstructured":"Furqan F, Fenske TS, Longo WL, Johnson B, Hamadani M, Shah NN. MRD Status By Clonoseq \u00ae is a poor predictor of long-term outcomes after bispecific lv20.19 CAR t-cell therapy for relapsed. Refractory B-Cell NHL Blood. 2022;140:6407\u20138.","journal-title":"Refractory B-Cell NHL. Blood"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01620-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01620-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T01:21:38Z","timestamp":1734139298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01620-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01620-8","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"23 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}